Patents by Inventor Heike DAHMEN

Heike DAHMEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF A PD-1 ANTAGONIST, AN ATR INHIBITOR AND A PLATINATING AGENT FOR THE TREATMENT OF CANCER
    Publication number: 20220048997
    Abstract: The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises a PD-1 antagonist, an ATR inhibitor and a platinating agent.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 17, 2022
    Inventors: Marat Alimzhanov, Patricia Soulard, Frank Zenke, Heike Dahmen, Astrid Zimmermann, Andreas Schroeder, Keyvan Tadjalli Mehr, Martin Falk
  • COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS
    Publication number: 20210369705
    Abstract: The present invention relates to synergistic combinations of DNA-alkylating ADCs and ATR inhibitors.
    Type: Application
    Filed: October 14, 2019
    Publication date: December 2, 2021
    Applicant: Merck Patent GmbH
    Inventors: Carl DEUTSCH, Birgit PIATER, Nicolas RASCHE, Heike DAHMEN, Frank ZENKE, Astrid ZIMMERMANN, Marcel RIEKER
  • COMPOUNDS AND USES THEREOF TO TREAT TUMORS IN A SUBJECT
    Publication number: 20210353614
    Abstract: The present invention relates to compounds that can be used to induce immunogenic cell death (ICD). In some instances, two or more compounds are combined to induce ICD. The invention also relates to the combination of ICD-inducing compounds with an agent stimulating the immune system, such as an immune checkpoint inhibitor, in particular, to 5 treat cancer or inhibit tumor growth.
    Type: Application
    Filed: March 13, 2019
    Publication date: November 18, 2021
    Inventors: Astrid Zimmermann, Maria Jesus Ortiz Ruiz, Heike Dahmen, Thomas Grombacher
  • Diagnostic anti-PD-L1 antibody and use thereof
    Patent number: 10738120
    Abstract: The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: August 11, 2020
    Assignees: Merck Patent GmbH, Pfizer Inc.
    Inventors: Claudia Wilm, Klaus Schneider, Heike Dahmen
  • Diagnostic Anti-PD-L1 Antibody and Use Thereof
    Publication number: 20190211104
    Abstract: The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.
    Type: Application
    Filed: September 20, 2017
    Publication date: July 11, 2019
    Applicants: Merck Patent GmbH, Pfizer Inc.
    Inventors: Claudia WILM, Klaus SCHNEIDER, Heike DAHMEN